(AOF) – Valbiotis drops 13.48% to 4.88 euros following the announcement of a capital increase with removal of preferential subscription rights and implementation of a priority period for the benefit of current shareholders of a amount of 15.0 million euros. 3.36 million new shares will be issued at a unit price of 4.46 euros. The food supplement specialist specifies that this price represents a facial discount of 20.1% compared to the closing price of December 8, 2023 (5.58 euros).
The company “is entering a new phase of deployment with the start of marketing” which, given its expectations, “requires additional financing”.
“To support this major transition, the company is launching a capital increase which aims to ensure its growth and enable the self-financing of its growth, while maintaining the focus on its current activities,” specifies Sébastien Peltier, Chairman of the Management Board and co-founder of Valbiotis. “With significant target markets, which are echoed in the news, the company is positioned to meet the immediate needs of millions of patients in the prevention of metabolic and cardiovascular diseases.”
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.